Kashiv BioSciences and MS Pharma have entered into a license and supply agreement for ADL-018, Kashiv BioSciences’ biosimilar candidate to Genentech and Novartis AG’s Xolair (omalizumab) in the Middle ...

Germany’s Formycon and Jordan-based MS Pharma have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon’s biosimilar candidate to the blockbuster drug ...

PISCATAWAY, N.J., August 05, 2025--(BUSINESS WIRE)--Kashiv BioSciences, LLC and MS Pharma today announced that the companies have entered into a license and supply agreement for ADL-018, Kashiv ...

RIYADH, Saudi Arabia, Aug. 27, 2025 /PRNewswire/ -- MS Pharma has officially inaugurated the first biologics' manufacturing facility in the Middle East, strategically located in Saudi Arabia. The ...

Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar ...

Polpharma Biologics S.A. (“Polpharma Biologics”), specialized in the development and manufacturing of biosimilars, today announced that it has signed licensing agreements with MS Pharma, a leading ...

Western drugmakers have been finding their way into the Middle East and North Africa, a market they see as having a lot of upside potential. But they are being met by some domestic companies, which ...